Agilent Technologies Stock: Analyst Estimates & Ratings
Agilent Technologies (A) has underperformed the broader market, with its stock declining 7.9% over the past year despite stable Q4 2025 results and a positive long-term outlook. Analysts expect a 6.1% year-over-year EPS increase for fiscal 2026, and the stock holds a "Moderate Buy" consensus rating from 18 analysts. The mean price target of $171.25 suggests a 35.5% premium to current price levels.
Agilent Technologies Stock: Analyst Estimates & Ratings
Agilent Technologies (A) has underperformed the broader market and the healthcare sector over the past year and year-to-date, despite stable fundamentals and a positive long-term outlook. Analysts maintain a "Moderate Buy" rating for the stock, with a consensus price target indicating a significant premium to current levels. The company's stock has faced downward pressure due to market concerns over global tariffs and supply chain issues, even as it continues to meet or exceed earnings expectations.
Agilent Technologies Shares: Expert Predictions and Evaluations
Agilent Technologies, a global supplier of laboratory instruments, has seen its shares underperform the broader market, dropping 7.9% in the last year due to cautious investor sentiment and profit-taking. Despite this, analysts have a "Moderate Buy" consensus, with an average price target of $171.25, indicating a potential upside of 35.5% amidst forecasts for a 6.1% increase in EPS for fiscal year 2026.
United States Cancer Biomarker Market is Going to Boom | Merck KGaA • QIAGEN • Illumina • Myriad Genetics
Coherent Market Insights has released a comprehensive report on the United States Cancer Biomarker Market, forecasting its growth from 2026-2033. The report analyzes market trends, competition, geographic distribution, and identifies key players such as Roche, Thermo Fisher Scientific, and Illumina. It also outlines market segmentation for diagnostics, prognostics, therapeutics, and personalized medicine, providing insights for stakeholders.
Liquid Handling System Market Is Going to Boom | Thermo Fisher Scientific • Eppendorf AG • Sartorius AG • Gilson Inc
A new report by Coherent Market Insights projects significant growth for the Liquid Handling System Market between 2026 and 2033, driven by various factors including increased demand and technological advancements. The comprehensive analysis covers market size, trends, competitive landscape, regional insights, and future growth opportunities. Key players identified include Thermo Fisher Scientific, Eppendorf AG, Sartorius AG, and Gilson Inc.
Spinal cord injury patients get new access as Aetna covers ReWalk exoskeleton
Lifeward (Nasdaq: LFWD) announced that Aetna has approved a prior authorization for a Medicare Advantage beneficiary to receive the ReWalk Personal Exoskeleton, deeming it medically necessary. This decision, following similar approvals from Humana and UnitedHealthcare, extends coverage for the ReWalk Personal Exoskeleton to approximately 16 million Medicare Advantage beneficiaries. The ReWalk Personal Exoskeleton is FDA-approved and backed by peer-reviewed studies highlighting its benefits for ambulation, musculoskeletal health, and cardiopulmonary function in individuals with spinal cord injuries.
Gas Chromatography Systems Market to Reach US$7.20 Billion
The global Gas Chromatography Systems Market is projected to reach US$7.20 billion by 2032, growing at an 8.8% CAGR from 2025 to 2032, up from US$3,668.75 million in 2024. This growth is driven by increasing demand for advanced analytical instrumentation in various sectors like environmental analysis, pharmaceuticals, and food safety, with North America leading the market. Key players like Thermo Fisher Scientific, Agilent Technologies, and Shimadzu Corporation are advancing the market through technological innovations in detector sensitivity, automation, AI integration, and the development of portable systems.
Gene Editing Market: Exploring Future Business Opportunities
This press release from Coherent Market Insights details a research report on the Gene Editing Market, forecasting substantial growth from 2026 to 2033. The report analyzes key market trends, drivers, challenges, and competitive landscapes, featuring major players like CRISPR Therapeutics and Editas Medicine. It provides insights into market segmentation, geographical landscapes, and future opportunities to aid businesses in strategic decision-making.
Vanguard Group Inc. Buys 124,481 Shares of Danaher Corporation $DHR
Vanguard Group Inc. increased its stake in Danaher Corporation by 0.2% in the third quarter, purchasing 124,481 additional shares to own a total of 60,894,068 shares valued at $12.07 billion. Danaher recently beat quarterly earnings expectations with $2.23 EPS and $6.84 billion in revenue. The stock, currently trading around $212.37, has a consensus "Moderate Buy" rating from analysts with an average target price of $253.86.
Waters Corporation (NYSE:WAT) Receives Average Recommendation of "Moderate Buy" from Brokerages
Waters Corporation (NYSE:WAT) has received an average rating of "Moderate Buy" from twenty-one brokerages, with an average 12-month target price of $397.68. This follows a Q4 earnings beat and strong FY-2026 guidance, attracting significant institutional investment, with Marshall Wace LLP notably increasing its stake. Despite a recent price target cut from Bank of America, the overall sentiment remains positive due to strong fundamentals and analyst coverage.
Agilent Technologies Stock: Quiet Rally, Hard Questions – Is The Lab Giant Still A Buy After Its Comeback?
Agilent Technologies has shown resilient performance, outperforming the broader market despite challenges in lab spending. The company's stock has rebounded, leading to questions about its future upside. Analysts are cautiously optimistic following recent earnings, with price targets suggesting further, albeit modest, gains.
Revvity Expands Drug Discovery Tools As Investors Weigh Growth And Valuation
Revvity (NYSE:RVTY) has launched new high-throughput drug discovery platforms at SLAS2026, including advanced screening systems and liquid handlers, to expand its life sciences tool portfolio. This move aims to deepen its presence across the drug discovery workflow, offering more integrated solutions. Investors will monitor the adoption of these new products by pharma and biotech customers, especially given Revvity's recent financial performance and future organic growth forecasts, as they weigh the company's growth potential against its current valuation and competitive landscape.
Revvity Expands Drug Discovery Tools As Investors Weigh Growth And Valuation
Revvity (NYSE:RVTY) has launched new high-throughput drug discovery platforms, including an advanced high-content screening system and a compact liquid handler, aiming to enhance laboratory efficiency. This strategic expansion follows recent financial results showing US$2.86 billion in 2025 sales and US$241.2 million in net income, and comes as the company's stock has seen a significant decline over the past year. Investors are now closely watching how these new offerings will be adopted by the market and contribute to Revvity's projected 2% to 3% organic growth for 2026, considering potential execution risks and competition.
Revvity Expands Drug Discovery Tools As Investors Weigh Growth And Valuation
Revvity (NYSE:RVTY) introduced new discovery platforms at SLAS2026 to enhance high-throughput drug discovery. These products include an advanced high-content screening system, a multimode plate reader, and a compact liquid handler, aiming to provide more integrated solutions. Investors are watching how these launches impact the company's 2026 revenue guidance and its competition with other large tools providers.
The Bull Case For Agilent Technologies (A) Could Change Following New PD-L1 Test Approval And Dividend News
Agilent Technologies announced a quarterly dividend of US$0.255 per share and received U.S. FDA approval for its PD-L1 IHC 22C3 pharmDx companion diagnostic for Keytruda in various cancers, including epithelial ovarian carcinoma. This approval enhances Agilent's role in precision oncology diagnostics, complementing its focus on recurring revenue streams and lab automation to support earnings resilience amidst cost inflation and funding pressures. The company projects $8.0 billion revenue and $1.7 billion earnings by 2028, with a fair value estimate of $169.67.
The Bull Case For Agilent Technologies (A) Could Change Following New PD-L1 Test Approval And Dividend News
Agilent Technologies announced a quarterly dividend of US$0.255 per share and received U.S. FDA approval for its PD-L1 IHC 22C3 pharmDx companion diagnostic, broadening its role in precision oncology. This approval, coupled with Agilent's focus on automation and AI-enabled solutions, strengthens its long-term investment narrative despite near-term challenges like tariff-driven cost inflation. The company forecasts $8.0 billion in revenue and $1.7 billion in earnings by 2028, with a fair value projection of $169.67.
Agilent Technologies, Inc. $A Shares Sold by ING Groep NV
ING Groep NV reduced its stake in Agilent Technologies (NYSE:A) by 36.7% in the third quarter, selling 9,691 shares, though other institutional investors like Brighton Jones LLC and Acadian Asset Management LLC increased their holdings. Agilent Technologies reported strong Q3 earnings, beating consensus estimates, and analysts have issued several "buy" ratings with increased price targets. The company also announced a quarterly dividend and saw insider activity with sales by its CEO and VP.
Assessing Revvity (RVTY) Valuation After Recent Share Price Weakness
Revvity's stock has seen recent weakness, declining 13.89% over the past month, but is currently indicated as undervalued by Simply Wall St's models. The company's valuation is driven by an ongoing shift towards higher margin, recurring revenue products and services, with an estimated fair value of US$114.63 against its current US$96.03 share price. However, investors face risks including regulatory changes in China and a high P/E ratio compared to the sector average.
Danaher Board Change As Jessica Mega Retires And Governance Focus Grows
Danaher Corporation announced the retirement of Dr. Jessica L. Mega from its Board of Directors, effective February 5, 2026, due to other professional commitments. This change is considered a material governance event, though Danaher clarified there are no disagreements. Investors are advised to monitor the board's future appointments and how Danaher navigates sector pressures like constrained biotech funding and pricing challenges in China.
How is Agilent Technologies' stock performance compared to other healthcare stocks?
This article provides a comparison of Agilent Technologies' (A) stock performance against other healthcare stocks. It analyzes key financial metrics and market trends to give readers a perspective on how Agilent stands within its industry.
Agilent Technologies, Inc. (NYSE:A) Receives Average Rating of "Moderate Buy" from Analysts
Agilent Technologies, Inc. (NYSE:A) has received a consensus "Moderate Buy" rating from analysts, with an average 1-year target price of $164.50. Recent analyst reports have included price target increases and "buy" or "overweight" ratings from firms like Citigroup and JPMorgan Chase & Co. The company reported strong financial performance, including a beat on quarterly earnings and revenue, and declared a quarterly dividend of $0.255 per share.
3 Profitable Stocks We Steer Clear Of
This article identifies three profitable companies—IDEX (IEX), CooperCompanies (COO), and Agilent (A)—that StockStory advises investors to avoid despite their current profitability. The author explains the reasons for caution for each company, citing issues like lack of organic growth, declining free cash flow margins, and waning returns on capital, and suggests exploring other high-quality stock opportunities.
Agilent Technologies, Inc. (NYSE:A) to Issue $0.26 Quarterly Dividend
Agilent Technologies (NYSE:A) has declared a quarterly dividend of $0.255 per share, payable on April 22 to stockholders of record on March 31. This represents an annual dividend of $1.02 and a yield of approximately 0.8%, with the company consistently increasing its dividend for nine consecutive years. Agilent recently surpassed quarterly EPS estimates and provided positive FY2026 guidance, maintaining a "Moderate Buy" consensus rating among analysts.
RFG Advisory LLC Has $1.20 Million Stake in Danaher Corporation $DHR
RFG Advisory LLC significantly reduced its stake in Danaher Corporation (NYSE:DHR) by 54.8% in Q3, selling 7,311 shares and holding 6,027 shares valued at approximately $1.20 million. Despite this, other institutional investors have recently acquired positions in Danaher, and company insiders own 11.10% of the stock. Danaher reported strong quarterly earnings, beating analyst estimates, and analysts maintain a "Moderate Buy" rating with a consensus price target of $253.86.
Positive Sentiment Still Eludes Codexis, Inc. (NASDAQ:CDXS) Following 29% Share Price Slump
Codexis, Inc. (NASDAQ:CDXS) has experienced a 29% share price drop in the last month and a 71% decline over the past year, leading to a low price-to-sales (P/S) ratio of 2x. Despite its revenue decreasing by 18% in the last year, analysts forecast a 32% annual revenue growth for the next three years, significantly higher than the industry average. The low P/S ratio, despite strong growth forecasts, suggests investor skepticism regarding potential risks and future revenue volatility.
Press Release: Agilent Announces Cash Dividend of 25.5 Cents per Share
Agilent Technologies Inc. (NYSE: A) has announced a quarterly dividend of 25.5 cents per share of common stock. The dividend is scheduled to be paid on April 22, 2026, to shareholders of record as of March 31, 2026. Agilent is a global leader in analytical and clinical laboratory technologies, reporting revenues of $6.95 billion in fiscal year 2025.
Own Agilent stock by March 31? A $0.255 cash payout is coming in April
Agilent Technologies Inc. declared a quarterly dividend of 25.5 cents per share of common stock. Shareholders of record as of March 31, 2026, will receive this dividend on April 22, 2026. This announcement highlights the company's commitment to returning value to its investors, with future dividend determinations subject to board approval.
Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (EOC)
Agilent Technologies announced FDA approval for its PD-L1 IHC 22C3 pharmDx, a companion diagnostic for identifying patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (EOC) who may benefit from Merck's KEYTRUDA. This marks the seventh FDA-approved companion diagnostic indication for the product. The approval is a significant step in advancing precision oncology for EOC, a disease with limited treatment options and a challenging prognosis.
Avantor Inc (AVTR) Stock Price, Quote, News & History
Avantor Inc.'s stock (AVTR) fell significantly after its Q4 2025 earnings release, which included soft guidance for 2026 and a projected revenue decline. The CEO outlined an investment year and a turnaround plan, acknowledging margin pressures. Analyst consensus indicates a "Hold" rating with a price target of $18.14, while the stock currently trades at $9.64.
Agilent Announces Cash Dividend of 25.5 Cents per Share
Agilent Technologies Inc. announced a quarterly dividend of 25.5 cents per share of common stock. The dividend will be paid on April 22, 2026, to shareholders of record as of March 31, 2026. This announcement highlights Agilent's commitment to returning value to its shareholders, with future dividends subject to board approval.
Agilent Announces Cash Dividend of 25.5 Cents per Share
Agilent Technologies Inc. announced a quarterly cash dividend of 25.5 cents per share of common stock. This dividend will be paid on April 22, 2026, to shareholders of record as of March 31, 2026. Agilent is a global leader in analytical and clinical laboratory technologies, generating $6.95 billion in revenue in fiscal year 2025.
Agilent Announces Cash Dividend of 25.5 Cents per Share
Agilent Technologies Inc. (NYSE: A) has declared a quarterly cash dividend of 25.5 cents per share of common stock. This dividend will be paid on April 22, 2026, to shareholders on record as of March 31, 2026. The company, a global leader in analytical and clinical laboratory technologies, generated $6.95 billion in revenue in fiscal year 2025.
Agilent Announces Cash Dividend of 25.5 Cents per Share
Agilent Technologies Inc. (NYSE: A) declared a quarterly cash dividend of 25.5 cents per share of common stock. The dividend is scheduled for payment on April 22, 2026, to shareholders recorded as of March 31, 2026. Agilent, a global leader in analytical and clinical laboratory technologies, reported revenues of $6.95 billion in fiscal year 2025 and employs approximately 18,000 people worldwide.
Agilent Slumps After Awarding Boehringer
Agilent Technologies Inc. announced that Boehringer Ingelheim received its first Instrument Trade In Impact Award for exceptional sustainability leadership by diverting 6,600 kg of instrument waste from landfills in 2025. This recognized Boehringer Ingelheim's contribution to a circular economy through Agilent's trade-in and buyback program, though Agilent's shares subsequently saw a slight decline.
Agilent Presents Boehringer Ingelheim With Inaugural 2025 Instrument Trade‑In Impact Award
Agilent Technologies announced Boehringer Ingelheim as the winner of its inaugural Instrument Trade‑In Impact Award for exceptional sustainability leadership. Boehringer Ingelheim's participation in Agilent's trade-in and buyback program in 2025 led to the diversion of 6,600 kg of instrument waste from landfills, demonstrating a strong commitment to circular economy practices. This award highlights the importance of industry partnerships in advancing environmental sustainability and responsible lifecycle management of scientific equipment.
Agilent presents Boehringer Ingelheim with inaugural 2025 instrument Trade-in Impact Award
Agilent Technologies awarded Boehringer Ingelheim the inaugural 2025 Instrument Trade-in Impact Award for its commitment to sustainability by recycling older instruments. Boehringer Ingelheim is lauded for its significant contribution to minimizing landfill waste and reducing raw material consumption through Agilent's trade-in program. This initiative aligns with both companies' dedication to sustainable practices in scientific instrumentation.
Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (EOC)
Agilent Technologies announced that the FDA has approved its PD-L1 IHC 22C3 pharmDx as the sole approved companion diagnostic for identifying first-line patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (EOC) eligible for treatment with Merck's KEYTRUDA (pembrolizumab). This marks the seventh FDA-approved companion diagnostic indication for the product with KEYTRUDA. The approval is a significant step in advancing precision medicine for EOC patients, a disease with limited therapeutic options and a low 5-year survival rate.
Agilent Presents Boehringer Ingelheim With Inaugural 2025 Instrument Trade‑In Impact Award
Agilent Technologies has recognized Boehringer Ingelheim with its inaugural Instrument Trade-In Impact Award for their leading efforts in sustainable laboratory practices. Boehringer Ingelheim's participation in Agilent's trade-in and buyback program resulted in the diversion of 6,600 kg of instrument waste from landfills in 2025, promoting a circular economy for scientific equipment. This award highlights Boehringer Ingelheim's commitment to sustainability and Agilent's role in supporting environmentally responsible practices within the scientific community.
Waters Corporation $WAT Stock Holdings Decreased by Madison Asset Management LLC
Madison Asset Management LLC reduced its stake in Waters Corporation (NYSE:WAT) by 1.5% in the third quarter, while institutional ownership remains high at 94.01%. Despite beating Q4 earnings estimates, Waters experienced share weakness due to Q1 2026 guidance falling below street expectations. Analysts hold a "Moderate Buy" rating, with an average target price of $400.84, although some firms adjusted targets due to integration risks with BD’s Biosciences & Diagnostic Solutions.
Madison Asset Management LLC Sells 14,089 Shares of Agilent Technologies, Inc. $A
Madison Asset Management LLC reduced its stake in Agilent Technologies, Inc. (NYSE:A) by 2.1% in the third quarter, selling 14,089 shares. The firm now owns 653,819 shares worth approximately $83.92 million. This comes amidst other institutional investors also adjusting their positions in the company, showcasing varied investment strategies.
FDA approves first immunotherapy-linked test to guide ovarian cancer care
Agilent Technologies announced that the U.S. FDA has approved its PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic for first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (EOC). This test identifies patients whose tumors express PD-L1 and may be eligible for treatment with Merck's KEYTRUDA® (pembrolizumab). This approval marks the seventh FDA-approved companion diagnostic indication for the test, expanding treatment options for EOC, a disease with a challenging prognosis.
Gas Chromatography Detector Market Is Going to Boom |• Agilent Technologies • Thermo Fisher Scientific
Worldwide Market Reports has published a comprehensive study on the "Gas Chromatography Detector Market Size and Forecast 2026-2033," analyzing growth trends, drivers, and challenges. The report provides detailed insights into market segmentation by types and applications, regional performance, and profiles key players like Agilent Technologies and Thermo Fisher Scientific. It also utilizes analytical tools such as SWOT and Porter's Five Forces to assess the competitive landscape.
Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (EOC)
Agilent Technologies Inc. announced that the FDA has approved its PD-L1 IHC 22C3 pharmDx for identifying first-line patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (EOC) who may be eligible for KEYTRUDA® treatment. This approval marks the first immuno-oncology approval for this disease, expanding precision medicine options. The diagnostic enables pathologists to assess PD-L1 expression early, supporting informed treatment decisions in a disease with limited therapeutic options.
Agilent Technologies, Inc. $A Position Cut by Impax Asset Management Group plc
Impax Asset Management Group plc reduced its stake in Agilent Technologies (NYSE:A) by 2.0% in the third quarter, though it remains a significant holding, valued at approximately $380.15 million. The company reported strong earnings, beating analyst estimates, and increased its quarterly dividend. Analysts maintain a "Moderate Buy" rating with a consensus price target of $164.50.
Ngs Oncology Market Is Going to Boom | Illumina • Roche • Thermo Fisher Scientific
A new report by Coherent Market Insights analyzes the global NGS Oncology Market, highlighting its rapid growth driven by rising demand and innovation. The report provides a comprehensive segmentation, competitive analysis of key players like Illumina and Roche, and forecasts substantial growth from 2026 to 2033. It offers insights into market trends, drivers, challenges, and strategic opportunities for industry leaders and investors.
Revvity Expands Automation Platforms At SLAS2026 As Investors Weigh Long Term Upside
Revvity (NYSE:RVTY) introduced new discovery and automation platforms at SLAS2026, including high content screening systems, plate readers, and workstations, signaling a deeper push into high throughput drug discovery and lab automation. These launches align with the industry's demand for more efficient and reproducible research workflows and could strengthen Revvity's position in genomics and lab automation. Investors will monitor the adoption of these systems, order trends, and potential broader collaborations, while also considering risks such as competition and regulatory pressures.
Agilent Unveils the 8850 Gas Chromatograph: A Leap Forward in Analytical Excellence
Agilent Technologies Inc. (NYSE: A) announced the launch of its 8850 Gas Chromatograph (GC) System, a compact, single-channel instrument that combines the capabilities of previous models with enhanced intelligence. This new GC aims to revolutionize labs in energy, chemicals, food, and pharmaceuticals by offering speed, efficiency, and a reduced energy footprint of up to 30%. Its small size and intelligent features address the modern lab's need for maximized analytical capacity, efficient space utilization, and sustainability without compromising performance.
Candriam S.C.A. Increases Holdings in Agilent Technologies, Inc. $A
Candriam S.C.A. significantly increased its stake in Agilent Technologies, Inc. (NYSE:A) by 65.4% in the third quarter, bringing its total holdings to 882,230 shares valued at approximately $113.23 million. This increase positions Candriam S.C.A. as a notable institutional investor in Agilent, which recently surpassed its earnings and revenue estimates and provided positive FY2026 guidance. Analyst sentiment remains largely positive for Agilent, with a "Moderate Buy" consensus and an average price target of $164.50, driven by several firms raising their targets to between $165 and $180.
Federated Hermes Inc. Has $273,000 Stock Position in Agilent Technologies, Inc. $A
Federated Hermes Inc. significantly reduced its stake in Agilent Technologies, selling 82.7% of its shares in Q3, now holding 2,128 shares valued at $273,000. Despite this, institutional ownership remains high at 87.41%, with major holders like Vanguard and Massachusetts Financial Services increasing their positions. Analysts maintain a "Moderate Buy" consensus for Agilent, with an average price target of $164.50, and the company recently increased its quarterly dividend.
Envestnet Asset Management Inc. Raises Holdings in Agilent Technologies, Inc. $A
Envestnet Asset Management Inc. increased its stake in Agilent Technologies (NYSE:A) by 3.8% in Q3, bringing its total holdings to 607,914 shares valued at $78 million. Other institutional investors also adjusted their positions in the medical research company. Agilent recently reported Q3 earnings that slightly beat expectations and raised its quarterly dividend to $0.255, with analysts largely maintaining a "Moderate Buy" rating.
